 Crinetics Pharmaceuticals NASDAQ:CRNX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Friday, Zacks.com reports. The firm currently has a 17.00 price objective on the stock. Zacks Investment Researchs price target indicates a potential upside of 10.75 from the companys previous close. According to ... 